Compare RAPP & KELYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAPP | KELYB |
|---|---|---|
| Founded | 2022 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Professional Services |
| Sector | | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 814.8M |
| IPO Year | 2024 | 1994 |
| Metric | RAPP | KELYB |
|---|---|---|
| Price | $39.66 | $22.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $48.50 | N/A |
| AVG Volume (30 Days) | ★ 275.9K | 13.1K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.95% |
| EPS Growth | ★ 24.34 | N/A |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $5,355,600,000.00 |
| Revenue This Year | N/A | $0.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $147.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.75 | $8.38 |
| 52 Week High | $52.93 | $125.00 |
| Indicator | RAPP | KELYB |
|---|---|---|
| Relative Strength Index (RSI) | 30.72 | 46.91 |
| Support Level | $38.95 | $21.49 |
| Resistance Level | $40.61 | $24.77 |
| Average True Range (ATR) | 2.06 | 0.77 |
| MACD | -0.92 | -0.22 |
| Stochastic Oscillator | 4.72 | 13.22 |
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.